Fig. 2

Overall survival in subgroups in dependence of the administered LT modality a) LT(+) of patients receiving radiotherapy as first LT(+) vs. LT(-) (LT(+): 29.8 (95%-CI: 24.2–35.4) vs. LT(-): 20.3 (95%-CI: 10.3–30.3) months, log-rank, p = 0.89). b) LT(+) of patients receiving surgery as first local therapy vs. LT(-) (LT(+): 49.6 (95%-CI: 34.7–64.5) vs. (LT(-): 20.3 (95%-CI: 10.3–30.3) months, log-rank p = 0.01). c) LT(-) vs. LT(+) with patients defined by local progression of mRCC vs. LT(+) defined by systemic progression of mRCC (LT(-): 20.3 (95%-CI: 10.3–30.3) vs. LT(+) local PD: 44 (95%-CI: 31.5–56.5) vs. (LT(+) systemic PD: 29.6 (95%-CI: 23.4–35.8) months, log-rank p = 0.03).